access
129 results
1 - 100- Differences in U.S. and Canadian Pharmaceutical Practices
- alteplase
- reteplase
- urokinase
- remdesivir
- Controlled Substances Schedules
- eptifibatide
- cerliponase alfa
- retapamulin
- ibritumomab
- bivalirudin
- tirofiban
- peginesatide
- molnupiravir
- C1-esterase inhibitor, recombinant
- calcipotriene
- magnesium sulfate (parenteral)
- epoprostenol
- nesiritide
- coagulation factor XIII A-subunit (recombinant)
- alemtuzumab
- sipuleucel
- Detecting and Managing Adverse Drug Reactions
- echinacea
- remifentanil
- treprostinil (parenteral)
- vigabatrin
- rocuronium
- eteplirsen
- opioid analgesics
- loxapine
- cisatracurium
- vecuronium
- chlorpheniramine polistirex/codeine polistirex
- Evidence-based Practice and Pharmacotherapeutics
- atracurium
- adenosine
- succinylcholine
- FENTANYL (transmucosal)
- central nervous system stimulants
- guaiFENesin
- pancuronium
- ibalizumab
- abciximab
- NEUROMUSCULAR BLOCKING AGENTS (nondepolarizing)
- Davis’s Drug Guide for Nurses
- solriamfetol
- enoxaparin
- meperidine
- midazolam
- levETIRAcetam
- fentaNYL (transdermal)
- tenecteplase
- ziv-aflibercept
- butorphanol
- estazolam
- modafinil
- carisoprodol
- trilaciclib
- argatroban
- chlordiazePOXIDE
- flurazepam
- lipid emulsion, injectable
- daratumumab
- levorphanol
- nalbuphine
- teniposide
- SUFentanil
- lutetium lu 177 dotatate
- methoxy polyethylene glycol-epoetin beta
- oliceridine
- darbepoetin
- epoetin
- oxazepam
- cloBAZam
- daridorexant
- ALPRAZolam
- buprenorphine
- codeine
- tapentadol
- buprenorphine/naloxone
- Overview of Risk Evaluation and Mitigation Systems (REMS)
- lasmiditan
- HYDROcodone
- LORazepam